Across TCGA pan-cancer cohorts, MIR190B RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR190B’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR190B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR190B is over-expressed in tumor.
BRCA are the cancer types where MIR190B tumor–normal differential expression is most reproducible.